FIELD: medicine. SUBSTANCE: means is constituted by polyethylene oxide USR= 301. It is experimentally suggested to use high-molecular linear polymers concurrently with antiaggregation agents, e. g. aspirin, which intensifies their effect. EFFECT: higher effectiveness of aspirin. 8 dwg, 7 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR STUDYING ANTI-AGGREGATION ACTION OF PREPARATIONS BY DETERMINING BLOOD PLATELET AGGREGATION IN VITRO | 2000 |
|
RU2188419C2 |
METHOD FOR OPTIMIZATION OF ANTIAGGREGATIONAL THERAPY IN PATIENTS WITH CEREBROVASCULAR DISEASES | 2000 |
|
RU2188008C2 |
METHOD FOR DISCOVERING DISTURBED RHEOLOGICAL PROPERTIES OF BLOOD | 1991 |
|
RU2008674C1 |
METHOD FOR PATIENT-SPECIFIC SELECTION OF ANTIPLATELET DRUGS FOR PATIENTS IN NEED THEREOF | 2012 |
|
RU2499261C1 |
METHOD OF REDUCING AGGREGATION ACTIVITY OF PLATELETS in vitro | 2009 |
|
RU2410104C1 |
METHOD FOR DETECTING ANTIPLATELET DRUG RESISTANCE IN PATIENTS WITH PROGRESSING CEREBRAL ATHEROSCLEROSIS | 2012 |
|
RU2478965C1 |
ANTIAGGREGATION AGENT | 1983 |
|
RU2045264C1 |
NITROESTER OF OXIDIZED STARCH SODIUM SALT SHOWING ANTIAGGREGANT ACTION | 1991 |
|
RU2074195C1 |
METHOD OF EVALUATING THE EFFECTIVENESS OF NON-AGGREGATE PREPARATIONS AFFECTING THE METABOLISM OF ARACHIDONIC ACID BY INHIBITION OF CYCLOOXYGENASE-1 BOTH INDIVIDUALLY AND JOINTLY WITH ADP P2Y RECEPTOR ANTAGONIST ON PLATELET MEMBRANES OF THE BLOOD TO THE PATIENT RECEIVING NON-AGGREGATE PREPARATIONS | 2010 |
|
RU2442167C1 |
METHOD FOR EVALUATING AGGREGATION PROPERTIES OF BLOOD PLATELETS | 2001 |
|
RU2213976C2 |
Authors
Dates
1994-02-15—Published
1991-01-04—Filed